Rosenberg study opens wider door to personalized TCR therapies for cancer

A new study from TIL pioneer Steve Rosenberg adds to the momentum of personalized T cell therapies by suggesting blood can be as good a source of neoantigen-specific TCRs as tumor tissue.

The results, which focused on patients with commonly shared p53 "hotspot" mutations, indicate the potent effects of tumor infiltrating lymphocytes (TILs) on advanced solid tumors could become accessible without invasive surgeries. ...